Indication:
Management of Plasma urica acid levels in patients with leukaemia, lymphoma and solid tumor malignancies who are receiving anti-cancer therapy (Malignancy associated hyperuricemia).
Dosage: 0.2mg/kg as iv infusion over 30 mins daily for 5 days.
Storage: 2 - 8°c
Dilution:
1. Reconstitute with the diluent provided (1ml).
2. Mix by swirling very gently.
3. Required dose further dilute with 50 ml of NS.
4. Infuse the final solution over 30 mins.
5. Diluted solution should be used immediately (may be stored upto 24 hrs at 2 to 8°c)
Note: It should be infused through a seperate line, if use of seperate line is not possible the line should be flushed with atleast 15ml of normal saline (Posiflush) prior to and after infusion.
Precaution:
Patient at risk for tumor lysis syndrome and on treatment with Inj. Rasburicase should receive IV hydration according to standard medical practice for the management of plasma uric acid.
Contraindications:
Rasburicase is contraindicated in patients with hypersensitivity to any of its constituents. It is also contraindicated in patients with G6PD deficiency or those who have developed metamoglobenemia.
Overdosage:
According to the mechanism of action of Rasburnat (Rasburicase) an overdose will lead to low or undetectable plasma uric acid concentration, which has no known clinical consequences.
Patients receiving an overdose should be monitored, and general supportive measures should be initiated as no specific antidote for Rasburnat (Rasburicase) has been identified.
Apollo Main Hospital, Chennai
 - Indication, Dose, Dilution, Precautions, Contraindications and Overdose ){kind=link}
0 Comments